Redhill Biopharma Signed A Collaborative Research Agreement With Duke University School Of Medicine Outlining Plans For Multiple In Vivo Studies, To Test Opaganib As A Potential Medical Countermeasure To Treat Phosgene Inhalation Injury
Redhill Biopharma Signed A Collaborative Research Agreement With Duke University School Of Medicine Outlining Plans For Multiple In Vivo Studies, To Test Opaganib As A Potential Medical Countermeasure To Treat Phosgene Inhalation Injury
redhill biopharma與杜克大學醫學院簽署合作研究協議，規劃進行多項體內研究，測試Opaganib作爲潛在的醫療對策，治療光氣吸入傷。
Under this research agreement, RedHill will provide required drug quantities for animal studies, analytical support to quantify drug concentrations in plasma samples, and share dosing regimen with the Achanta Lab at Duke University.
根據此研究協議，redhill biopharma將提供動物研究所需的藥物量，分析支持以量化血漿樣本中藥物濃度，並與杜克大學的Achanta實驗室分享給藥方案。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間